XBiotech Inc (XBIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XBiotech Inc (XBIT) has a cash flow conversion efficiency ratio of -0.164x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.95 Million) by net assets ($140.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XBiotech Inc (XBIT) net asset quality to measure how much of total assets are equity-financed.
XBiotech Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how XBiotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check XBIT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
XBiotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XBiotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Infragreen Group Ltd
AU:IFN
|
-0.004x |
|
C3 Metals Inc
V:CCCM
|
-0.012x |
|
Sewoon Medical Co. Ltd
KQ:100700
|
0.019x |
|
Dutaland Bhd
KLSE:3948
|
-0.019x |
|
Yong Pyong Resort Corp
KO:070960
|
0.006x |
|
Trans Polonia S.A.
WAR:TRN
|
0.021x |
|
24SevenOffice Scandinavia AB
ST:247
|
-0.112x |
|
Kula Gold Ltd
AU:KGD
|
-0.204x |
Annual Cash Flow Conversion Efficiency for XBiotech Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of XBiotech Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see XBiotech Inc (XBIT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $140.35 Million | $-39.92 Million | -0.284x | -67.43% |
| 2024-12-31 | $182.27 Million | $-30.96 Million | -0.170x | -98.54% |
| 2023-12-31 | $218.85 Million | $-18.73 Million | -0.086x | -38.76% |
| 2022-12-31 | $240.40 Million | $-14.82 Million | -0.062x | -123.92% |
| 2021-12-31 | $269.38 Million | $69.44 Million | 0.258x | +237.95% |
| 2020-12-31 | $348.64 Million | $-65.15 Million | -0.187x | -672.86% |
| 2019-12-31 | $755.63 Million | $-18.27 Million | -0.024x | +93.95% |
| 2018-12-31 | $41.40 Million | $-16.54 Million | -0.399x | +28.58% |
| 2017-12-31 | $60.16 Million | $-33.65 Million | -0.559x | +28.21% |
| 2016-12-31 | $59.06 Million | $-46.02 Million | -0.779x | -141.03% |
| 2015-12-31 | $103.05 Million | $-33.31 Million | -0.323x | -63.08% |
| 2014-12-31 | $59.03 Million | $-11.70 Million | -0.198x | +77.24% |
| 2013-12-31 | $10.23 Million | $-8.91 Million | -0.871x | +44.81% |
| 2012-12-31 | $7.37 Million | $-11.63 Million | -1.578x | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more